Literature DB >> 20195728

Prostaglandin I(2) analogues enhance growth-related oncogene-alpha expression in human monocyte-derived dendritic cells.

Chang-Hung Kuo1, Ren-Long Jan, Yu-Te Chu, Wei-Li Wang, Ming-Yii Huang, Ching-Hua Huang, Tai-Heng Chen, Chih-Hsing Hung.   

Abstract

Chemokines for neutrophils such as growth-related oncogene-alpha (GRO-alpha) are important in patients with refractory or severe asthma. Prostaglandin I(2) (PGI(2)) analogues were regarded as potential treatments for asthma. Dendritic cells (DCs) are the professional antigen-presenting cells and play a critical role in regulating immune response. However, it is unknown whether PGI(2) analogues have regulatory effects on GRO-alpha expression in human monocyte-derived DCs (MDDCs). The human MDDCs were pretreated with iloprost and treprostinil (two PGI(2) analogues) or forskolin, a cyclic adenosine monophosphate (cAMP) activator, before stimulation with lipopolysaccharide (LPS). In some cases, I prostanoid (IP) receptor and E prostanoid (EP) antagonists were pretreated before PGI(2) analogue treatment. To investigate the intracellular signaling, nuclear factor (NF)-kappaB inhibitor and the mitogen-activated protein kinase (MAPK) inhibitors were pretreated before PGI(2) analogue treatment. GRO-alpha was measured by enzyme-linked immunosorbent assay. Intracellular signaling was also investigated by Western blot. Iloprost and treprostinil enhanced LPS-induced GRO-alpha expression in MDDCs. This effect could be reversed by an I prostanoid receptor antagonist, CAY10449, but not EP receptor antagonists. Forskolin conferred a similar modulating effect as that noted in iloprost- and treprostinil-treated MDDCs. PGI(2) analogue-enhanced LPS-induced GRO-alpha expression was reduced by MAPK-p38 inhibitor, SB203580. PGI(2) analogues enhanced LPS-induced phospho-p38 expression. PGI(2) analogues enhanced LPS-induced GRO-alpha expression via the IP receptor-cAMP and p38-MAPK pathways in human MDDCs, which may further recruit neutrophil accumulation and adversely affect patients with refractory or severe asthma because of airway neutrophilia. These effects should be considered for PGI(2) analogues as candidates for the treatment of asthma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20195728     DOI: 10.1007/s10753-010-9190-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  37 in total

Review 1.  Inflammatory mediators of asthma: an update.

Authors:  P J Barnes; K F Chung; C P Page
Journal:  Pharmacol Rev       Date:  1998-12       Impact factor: 25.468

2.  Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes.

Authors:  L C Meagher; J M Cousin; J R Seckl; C Haslett
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

Review 3.  New molecular targets for the treatment of neutrophilic diseases.

Authors:  Peter J Barnes
Journal:  J Allergy Clin Immunol       Date:  2007-03-13       Impact factor: 10.793

4.  Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa.

Authors:  Motonori Fukakusa; Celine Bergeron; Meri K Tulic; Pierre-Olivier Fiset; Oday Al Dewachi; Michel Laviolette; Qutayba Hamid; Jamila Chakir
Journal:  J Allergy Clin Immunol       Date:  2005-02       Impact factor: 10.793

5.  Induction of C-X-C chemokines, growth-related oncogene alpha expression, and epithelial cell-derived neutrophil-activating protein-78 by ML-1 (interleukin-17F) involves activation of Raf1-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase 1/2 pathway.

Authors:  Mio Kawaguchi; Fumio Kokubu; Satoshi Matsukura; Koushi Ieki; Miho Odaka; Shin Watanabe; Shintaro Suzuki; Mitsuru Adachi; Shau-Ku Huang
Journal:  J Pharmacol Exp Ther       Date:  2003-10-13       Impact factor: 4.030

6.  Neutrophilic inflammation and CXC chemokines in patients with refractory asthma.

Authors:  Shinya Kikuchi; Izumi Kikuchi; Yotaro Takaku; Takehito Kobayashi; Koichi Hagiwara; Minoru Kanazawa; Makoto Nagata
Journal:  Int Arch Allergy Immunol       Date:  2009-06-03       Impact factor: 2.749

7.  Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids.

Authors:  R H Green; C E Brightling; G Woltmann; D Parker; A J Wardlaw; I D Pavord
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

8.  Suppressive effect on MDC and IP-10 expression in monocytes by endocrine disruptor chemicals.

Authors:  Ching-Hui Yeh; Hsaing-Chi Wu; Thai-Hung Kuo; Chang-Hung Kuo; San-Nan Yang; Wei-Li Wang; Huan-Nan Chen; Wan-Ju Wei; Chih-Hsing Hung
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

9.  CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality.

Authors:  Kaifeng Lisa Lin; Yasushi Suzuki; Hideki Nakano; Elizabeth Ramsburg; Michael Dee Gunn
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

10.  Modulation of cytokine expression in human myeloid dendritic cells by environmental endocrine-disrupting chemicals involves epigenetic regulation.

Authors:  Chih-Hsing Hung; San-Nan Yang; Po-Lin Kuo; Yu-Te Chu; Hui-Wen Chang; Wan-Ju Wei; Shau-Ku Huang; Yuh-Jyh Jong
Journal:  Environ Health Perspect       Date:  2010-01       Impact factor: 9.031

View more
  1 in total

1.  A rat model of exercise-induced asthma: a nonspecific response to a specific immunogen.

Authors:  Einat Kodesh; Frank Zaldivar; Christina Schwindt; Phuc Tran; Alvin Yu; Marinelle Camilon; Dwight M Nance; Szu-Yun Leu; Dan Cooper; Gregory R Adams
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-01-12       Impact factor: 3.619

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.